IL-2 Administration Increases CD4+ CD25(hi) Foxp3+ Regulatory T Cells in Cancer Patients

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2005 Nov 24

PMID 16304057

Citations 290

Authors

Mojgan Ahmadzadeh

Steven A Rosenberg

Affiliations

Soon will be listed here.

Abstract

Interleukin-2 (IL-2) is historically known as a T-cell growth factor. Accumulating evidence from knockout mice suggests that IL-2 is crucial for the homeostasis and function of CD4+ CD25+ regulatory T cells in vivo. However, the impact of administered IL-2 in an immune intact host has not been studied in rodents or humans. Here, we studied the impact of IL-2 administration on the frequency and function of human CD4+ CD25(hi) T cells in immune intact patients with melanoma or renal cancer. We found that the frequency of CD4+ CD25(hi) T cells was significantly increased after IL-2 treatment, and these cells expressed phenotypic markers associated with regulatory T cells. In addition, both transcript and protein levels of Foxp3, a transcription factor exclusively expressed on regulatory T cells, were consistently increased in CD4 T cells following IL-2 treatment. Functional analysis of the increased number of CD4+ CD25(hi) T cells revealed that this population exhibited potent suppressive activity in vitro. Collectively, our results demonstrate that administration of high-dose IL-2 increased the frequency of circulating CD4+ CD25(hi) Foxp3+ regulatory T cells. Our findings suggest that selective inhibition of IL-2-mediated enhancement of regulatory T cells may improve the therapeutic effectiveness of IL-2 administration.

Citing Articles

Efficacy Evaluation of "Enhanced" Natural Killers with and Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients.

Yuzhakova D, Sachkova D, Shirmanova M, Shcheslavskiy V, Mozherov A, Dashinimaev E Sovrem Tekhnologii Med. 2025; 17(1):109-118.

PMID: 40071076 PMC: 11892565. DOI: 10.17691/stm2025.17.1.10.

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Munoz-Couselo E, Soria Rivas A, Sandhu S, Long G, Sanmamed M, Spreafico A Cancer Res Commun. 2025; 5(2):358-368.

PMID: 39895413 PMC: 11848832. DOI: 10.1158/2767-9764.CRC-24-0601.

Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically 'cold' tumor models.

Kennedy B, Noftall E, Dean C, Roth A, Clark K, Rowles D Front Immunol. 2025; 15:1512543.

PMID: 39872527 PMC: 11769938. DOI: 10.3389/fimmu.2024.1512543.

Cytokines in cancer.

Kureshi C, Dougan S Cancer Cell. 2024; 43(1):15-35.

PMID: 39672170 PMC: 11841838. DOI: 10.1016/j.ccell.2024.11.011.

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies.

Tao Z, Chyra Z, Kotulova J, Celichowski P, Mihalyova J, Charvatova S Blood Cancer J. 2024; 14(1):213.

PMID: 39627220 PMC: 11615218. DOI: 10.1038/s41408-024-01193-6.

References

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

Ruprecht C, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A . Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med. 2005; 201(11):1793-803. PMC: 2213274. DOI: 10.1084/jem.20050085. View

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk A . Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001; 193(11):1285-94. PMC: 2193380. DOI: 10.1084/jem.193.11.1285. View

DIECKMANN D, Plottner H, Berchtold S, Berger T, Schuler G . Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001; 193(11):1303-10. PMC: 2193384. DOI: 10.1084/jem.193.11.1303. View

Baecher-Allan C, Brown J, Freeman G, Hafler D . CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001; 167(3):1245-53. DOI: 10.4049/jimmunol.167.3.1245. View

Furtado G, Curotto de Lafaille M, Kutchukhidze N, Lafaille J . Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med. 2002; 196(6):851-7. PMC: 2194060. DOI: 10.1084/jem.20020190. View

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

Malek T . The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003; 74(6):961-5. DOI: 10.1189/jlb.0603272. View

Aerts J, Gonzales M, Topalian S . Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques. 2004; 36(1):84-6, 88, 90-1. DOI: 10.2144/04361ST04. View

10.

Baecher-Allan C, Viglietta V, Hafler D . Human CD4+CD25+ regulatory T cells. Semin Immunol. 2004; 16(2):89-98. DOI: 10.1016/j.smim.2003.12.005. View

11.

Thornton A, Donovan E, Piccirillo C, Shevach E . Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol. 2004; 172(11):6519-23. DOI: 10.4049/jimmunol.172.11.6519. View

12.

Malek T, Bayer A . Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004; 4(9):665-74. DOI: 10.1038/nri1435. View

13.

Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S . Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 2004; 16(11):1643-56. DOI: 10.1093/intimm/dxh165. View

14.

Morgan D, Ruscetti F, Gallo R . Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976; 193(4257):1007-8. DOI: 10.1126/science.181845. View

15.

Depper J, Leonard W, Drogula C, Kronke M, Waldmann T, Greene W . Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A. 1985; 82(12):4230-4. PMC: 397970. DOI: 10.1073/pnas.82.12.4230. View

16.

de Jong R, Brouwer M, Hooibrink B, van der Pouw-Kraan T, Miedema F, van Lier R . The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol. 1992; 22(4):993-9. DOI: 10.1002/eji.1830220418. View

17.

Rosenberg S, Yang J, Topalian S, Schwartzentruber D, Weber J, Parkinson D . Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994; 271(12):907-13. View

18.

Hamann D, Baars P, Rep M, Hooibrink B, Klein M, van Lier R . Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997; 186(9):1407-18. PMC: 2199103. DOI: 10.1084/jem.186.9.1407. View

19.

Antony P, Restifo N . CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005; 28(2):120-8. PMC: 1242172. DOI: 10.1097/01.cji.0000155049.26787.45. View

20.

Antony P, Piccirillo C, Akpinarli A, Finkelstein S, Speiss P, Surman D . CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005; 174(5):2591-601. PMC: 1403291. DOI: 10.4049/jimmunol.174.5.2591. View